IRD Q3 2023 Earnings — Opus Genetics, Inc. Revenue & Financial Results | Market Cap Arena

IRDOpus Genetics, Inc.

$349M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M

Gross Profit

$12M100.0% margin

Operating Income

$6M53.5% margin

Net Income

$6M46.6% margin

EPS (Diluted)

$0.25

QoQ Revenue Growth

+224.9%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$573,000

Balance Sheet

Total Assets

$54M

Total Liabilities

$4M

Stockholders' Equity

$50M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$0	—
Gross Profit	$12M	$0	—
Operating Income	$6M	-$5M	+240.7%
Net Income	$6M	-$5M	+222.7%